H.R. 1266: Combating Illicit Xylazine Act

H.R. 1266 would add xylazine to Schedule III under federal drug law, making it a controlled substance with criminal penalties for illegal trafficking and stricter rules for handling it. In plain terms, Congress is trying to treat illicit xylazine more like other regulated drugs, while still allowing approved animal uses to continue.

The bill is built around a balancing act. Xylazine has real veterinary uses, so lawmakers do not ban it outright. Instead, they create a special framework for who can legally possess it, mainly veterinarians, pharmacies filling veterinary prescriptions, animal owners, animal care operations, government animal-control programs, and wildlife programs. That is meant to stop diversion into the illicit market without disrupting normal animal care.

The measure also gives the industry a transition period. Some Schedule III rules for labeling and packaging would wait a year, and practitioner registration and recordkeeping rules would phase in after 60 days. Existing manufacturers would also get relief from having to make new capital upgrades for certain Schedule III security standards, which suggests lawmakers are trying to avoid supply disruptions for legitimate veterinary products.

Beyond scheduling, the bill would expand federal tracking of xylazine through ARCOS, direct the U.S. Sentencing Commission to review penalties, and require federal reports to Congress on diversion, trafficking, origins, and possible xylazine-like substances. The politics are notable too: the bill has broad bipartisan backing, which gives it a stronger chance than many crime-and-drug-policy proposals, though lawmakers will still have to work through concerns about enforcement, veterinary access, and whether traffickers will simply switch to similar unscheduled substances.